Douglas H Thamm Selected Research

Douglas H Thamm Research Topics

Disease

53	Neoplasms (Cancer) 03/2022 - 08/2003
17	Lymphoma (Lymphomas) 01/2022 - 03/2002
15	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 01/2003
8	Neoplasm Metastasis (Metastasis) 01/2022 - 08/2008
5	Hemangiosarcoma (Angiosarcoma) 01/2022 - 08/2006
5	Sarcoma (Soft Tissue Sarcoma) 10/2021 - 11/2002
3	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2021
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/2010 - 05/2008
2	Leukemia 01/2022 - 01/2014
2	Melanoma (Melanoma, Malignant) 01/2022 - 02/2010
2	Disease Progression 10/2021 - 01/2007
2	Carcinoma (Carcinomatosis) 01/2019 - 09/2003
2	Diarrhea 01/2007 - 09/2005
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Glioma (Gliomas) 01/2022
1	Bone Neoplasms (Bone Cancer) 12/2021
1	Histiocytic Sarcoma 10/2021
1	Leiomyosarcoma 10/2021
1	Hyperplasia 10/2021
1	Liver Neoplasms (Liver Cancer) 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 09/2020
1	Circulating Neoplastic Cells 01/2019
1	Osteoporosis 12/2018

Drug/Important Bio-Agent (IBA)

17	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 11/2002
10	Biological ProductsIBA 01/2022 - 09/2003
8	Pharmaceutical PreparationsIBA 01/2022 - 06/2014
7	Proteins (Proteins, Gene)FDA Link 10/2021 - 02/2010
6	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 05/2008
6	rabacfosadineIBA 01/2022 - 05/2008
5	Vincristine (Oncovin)FDA LinkGeneric 03/2021 - 11/2002
5	Prednisone (Sone)FDA LinkGeneric 09/2020 - 01/2007
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2022 - 01/2003
4	Carboplatin (JM8)FDA LinkGeneric 10/2021 - 07/2004
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2021 - 10/2011
4	Messenger RNA (mRNA)IBA 03/2020 - 08/2003
3	Auranofin (Ridaura)FDA Link 06/2020 - 01/2018
3	Asparaginase (Elspar)FDA Link 03/2020 - 09/2005
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 08/2008
3	Peptides (Polypeptides)IBA 01/2018 - 09/2014
3	NucleotidesIBA 01/2014 - 05/2008
3	VaccinesIBA 01/2007 - 11/2002
2	toceranib phosphateIBA 03/2022 - 05/2014
2	Diphosphonates (Bisphosphonates)IBA 01/2022 - 12/2018
2	Lomustine (CCNU)FDA Link 03/2021 - 01/2007
2	SurvivinIBA 03/2020 - 01/2012
2	GuanineIBA 01/2014 - 05/2009
2	ProdrugsIBA 01/2014 - 05/2009
2	9-((2-phosphonylmethoxy)ethyl)guanineIBA 01/2014 - 05/2009
2	Histone Deacetylase InhibitorsIBA 03/2012 - 01/2011
2	Valproic Acid (Depakote)FDA LinkGeneric 01/2011 - 10/2010
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 02/2010 - 07/2004
2	IGF Type 1 Receptor (IGF 1 Receptor)IBA 02/2010 - 05/2004
1	NF-kappa B (NF-kB)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Angiotensin Receptor AntagonistsIBA 01/2022
1	Drug CombinationsIBA 01/2022
1	Losartan (Cozaar)FDA LinkGeneric 01/2022
1	Gemcitabine FDA Link 12/2021
1	Ibandronic Acid (Boniva)FDA Link 12/2021
1	Docetaxel (Taxotere)FDA Link 12/2021
1	Morphine (MS Contin)FDA LinkGeneric 11/2021
1	Histamine (Histamine Dihydrochloride)FDA Link 11/2021
1	Indicators and Reagents (Reagents)IBA 10/2021
1	RNA (Ribonucleic Acid)IBA 10/2021
1	DesminIBA 10/2021
1	Scavenger Receptors (Scavenger Receptor)IBA 10/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 10/2021
1	von Willebrand FactorIBA 10/2021
1	AntigensIBA 03/2021
1	Bovine Serum AlbuminIBA 01/2021
1	SiliconIBA 01/2021
1	IonsIBA 01/2021
1	Thioredoxin Reductase 2IBA 06/2020
1	Antisense OligonucleotidesIBA 03/2020
1	locked nucleic acidIBA 03/2020
1	EZN 3042IBA 03/2020
1	Inhibitor of Apoptosis ProteinsIBA 03/2020
1	Ivermectin (Mectizan)FDA Link 08/2019
1	Cisplatin (Platino)FDA LinkGeneric 01/2019
1	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2019
1	Antimicrobial PeptidesIBA 01/2019
1	Durapatite (Hydroxylapatite)IBA 12/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2018
1	Thioredoxin-Disulfide ReductaseIBA 05/2018
1	LigandsIBA 01/2018
1	Caspase 3 (Caspase-3)IBA 01/2018

Therapy/Procedure

26	Therapeutics 03/2022 - 03/2002
16	Drug Therapy (Chemotherapy) 01/2022 - 11/2002
5	Surgical Amputation (Amputations) 01/2022 - 03/2010
3	Radiotherapy 03/2022 - 01/2016
3	CHOP protocol (VDCP protocol) 09/2020 - 09/2005
2	Aftercare (After-Treatment) 10/2021 - 03/2020
2	Splenectomy 10/2021 - 07/2021
2	Immunotherapy 09/2019 - 08/2003
2	Combination Drug Therapy (Combination Chemotherapy) 01/2007 - 09/2005
1	Time-to-Treatment 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 09/2021
1	Precision Medicine 03/2021
1	Adjuvant Chemotherapy 01/2019